Canagliflozin Improves Risk Factors of Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus and Metabolic Syndrome
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s126291
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Informa UK Limited